Xeris Q2 Preview: 43% Growth Already Pushed 2026 Guidance Higher-What Has to Happen Next

Why Xeris' Q2 2026 print matters more than a typical earnings beat

Xeris' upcoming report is more than a routine checkpoint. After record Q2 2025 results and a full-year 2025 guidance raise, investors now expect another quarter of clean execution. That raises the stakes: a solid beat may be necessary, but it may not be enough on its own.

The hurdle is higher because Q1 was already strong. Xeris posted 43% year-over-year product revenue growth to over $82 million, while Recorlev net revenue reached $50 million. Management also raised the bottom end of its full year 2026 total revenue guidance to $380 million to $390 million. After that start, even steady execution may not be sufficient if underlying momentum looks less forceful than expected.

The catalyst setup is straightforward: Xeris releases Q2 results before the open on Thursday, with the 8:30 a.m. ET call doing the heavier lifting. If guidance moves higher again, investors are more likely to view that as evidence of durable commercial momentum. If it stays in line, the market may focus more closely on growth quality and Recorlev's contribution.

Recorlev still drives the valuation debate

Xeris can deliver another solid top-line quarter, but investors will focus on whether Recorlev remains the main acceleration engine. In Q1, Recorlev net revenue rose 95% year over year to $49.8 million against more than $82 million of product revenue. That keeps the debate centered on whether Xeris still has a single dominant growth driver rather than a fully diversified revenue base.

The recent benchmark still favors Recorlev-led upside

The recent baseline is aggressive. In Q2 2025, Xeris reported total revenue of $71.5 million, up 49%, while Recorlev revenue grew 136%. That makes this quarter less about headline growth and more about whether the franchise is still in a diffusion phase or starting to look more mature.

Full-year 2025 adds some nuance. In the fourth quarter of 2025, Recorlev still produced $45.3 million, but other products also contributed meaningfully. That suggests the portfolio is broadening, which is healthy over time. In the near term, though, it increases the pressure on Recorlev to keep delivering the kind of growth that has supported the stock's premium setup.

The patent backdrop helps, but it is not the near-term trading catalyst. Xeris has Orange Book-listed patents to 2040, which supports the durability argument around Recorlev. Still, the market is more likely to reward that durability if near-term commercial momentum still looks intact.

What management needs to prove on the Q2 call

Management does not need every franchise to explode. It needs to show that the core engine is still pulling harder, not merely holding the line. The key proof points are:

• Recorlev is still compounding rather than simply stabilizing at a high level.
• Commercial momentum looks organic, with continued signs that prescriber awareness and patient growth are still expanding.
• The expanded commercial team is building impact rather than still waiting on adoption.
• Guidance remains dynamic, ideally showing that the revenue outlook can move higher again.

If those signals strengthen together, Xeris can keep the market treating Recorlev as an accelerating asset. If they look weaker, investors are more likely to price normalization more quickly.

What would flip the setup from bullish to cautious

Xeris already has a recent pattern of record Q2 2025 results and a raised 2026 revenue guide. So the real question on the call is not whether the company can post another strong quarter. It is whether management sounds like a business still creating new demand or one defending a momentum narrative.

Bull case: the ramp is still widening

• Management needs to reinforce that growth is still being supported by growth across our patient base and increased awareness across the prescriber base.
• Another guidance increase would be a strong signal. After the full year 2026 total revenue guidance range of $375 million to $390 million and this year's updated outlook, another step up would suggest the runway is longer than expected.
• If management adds more detail around the commercial team expansion and how its impact is building through the second half of 2026, that would support confidence in future quarters.

Bear case: momentum starts to look harder to defend

• If management repeats the same growth narrative without adding new support, investors may treat it as a sign that the story is running ahead of fresh evidence.
• Guidance that holds steady could also weigh on sentiment after recent upward revisions.
• The setup weakens further if management implies the commercial build will take longer to show up, or if it stops linking Recorlev growth to clearer prescriber and patient momentum.

That is the split: confirmed diffusion into prescriptions, or a story starting to live off its own recent proof.